search
Back to results

A Study of Remimazolam Tosilate for Prolonged Sedation in the ICU

Primary Purpose

Sedation in the ICU

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
Remimazolam Tosilate
Sponsored by
Jiangsu HengRui Medicine Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sedation in the ICU

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients or their guardians are able to provide a written informed consent Subjects have been treated with endotracheal intubation and mechanical ventilation, and is expected to receive sedation after randomization. The target level and duration of sedation meet the criteria Age ≥ 18 and ≤ 80 years, male or female Body mass index (BMI) > 18 and < 30 kg/m2 Exclusion Criteria: participants (other than in endotracheal intubation) who are expected to require neuro-muscle blockers during sedation; Suffering from mental disorders (such as schizophrenia, depression, etc.) and cognitive dysfunction; Organ failure during screening period; Subjects who were receiving dialysis during the screening period or who were expected to require dialysis treatment during the study period; History of epilepsy or status epilepticus; Subjects with a history of drug abuse; Myasthenia gravis or a history of myasthenia gravis; severe arrhythmias or heart disease; Subjects after neurosurgery operation; participants who did not require continuous sedation during mechanical ventilation for endotracheal intubation; Abnormal values of the laboratory examination Subjects who required vasopressor medication to maintain normotensive blood pressure during the screening period (excluding subjects who used vasopressor medication only during surgery); Allergic to relevant drugs ingredient or component; Pregnant or nursing women; Subjects who has participated in clinical trials of other interventions recently; Other conditions deemed unsuitable to be included.

Sites / Locations

  • The Affiliated Hospital of Guizhou Medical UniversityRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Remimazolam Tosilate

Arm Description

IV of Remimazolam Tosilate

Outcomes

Primary Outcome Measures

Rate of sedation success, sedation success is defined as the percentage of time maintaining target sedation in the entire drug administering time ≥ 70% without rescue sedation.

Secondary Outcome Measures

Percentage of time maintaining target sedation in the entire drug administering time.
Percentage of subjects receiving rescue sedation and the average dosage of rescue sedation
Percentage of subjects receiving rescue analgesia and the average dosage of rescue analgesia
Wake-up time.
Evaluation of nursing difficulty.
Mechanical ventilation time.

Full Information

First Posted
June 13, 2023
Last Updated
June 27, 2023
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05913336
Brief Title
A Study of Remimazolam Tosilate for Prolonged Sedation in the ICU
Official Title
Evaluating the Efficacy and Safety of Remimazolam Tosilate for Injection for Prolonged Mechanical Ventilation Sedation in the Intensive Care Unit (ICU) - A Non-randomized, Multicenter, Single-arm, Open-label, Proof-of-concept, Phase I/II Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 27, 2023 (Actual)
Primary Completion Date
November 1, 2023 (Anticipated)
Study Completion Date
November 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Jiangsu HengRui Medicine Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the efficacy and safety of Remimazolam Tosilate for Injection for prolonged sedation(≥72h) during mechanical ventilation in the ICU.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sedation in the ICU

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Remimazolam Tosilate
Arm Type
Experimental
Arm Description
IV of Remimazolam Tosilate
Intervention Type
Drug
Intervention Name(s)
Remimazolam Tosilate
Intervention Description
Loading dose: 0.08mg/kg , Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.1-0.2mg/kg/h
Primary Outcome Measure Information:
Title
Rate of sedation success, sedation success is defined as the percentage of time maintaining target sedation in the entire drug administering time ≥ 70% without rescue sedation.
Time Frame
within 72 hours after administration of research drug
Secondary Outcome Measure Information:
Title
Percentage of time maintaining target sedation in the entire drug administering time.
Time Frame
within 72 hours after administration of research drug
Title
Percentage of subjects receiving rescue sedation and the average dosage of rescue sedation
Time Frame
within 72 hours after administration of research drug
Title
Percentage of subjects receiving rescue analgesia and the average dosage of rescue analgesia
Time Frame
within 72 hours after administration of research drug
Title
Wake-up time.
Time Frame
after stopping the research drug
Title
Evaluation of nursing difficulty.
Time Frame
follow-up period (approx. 5-10 minutes)
Title
Mechanical ventilation time.
Time Frame
at the time of extubation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients or their guardians are able to provide a written informed consent Subjects have been treated with endotracheal intubation and mechanical ventilation, and is expected to receive sedation after randomization. The target level and duration of sedation meet the criteria Age ≥ 18 and ≤ 80 years, male or female Body mass index (BMI) > 18 and < 30 kg/m2 Exclusion Criteria: participants (other than in endotracheal intubation) who are expected to require neuro-muscle blockers during sedation; Suffering from mental disorders (such as schizophrenia, depression, etc.) and cognitive dysfunction; Organ failure during screening period; Subjects who were receiving dialysis during the screening period or who were expected to require dialysis treatment during the study period; History of epilepsy or status epilepticus; Subjects with a history of drug abuse; Myasthenia gravis or a history of myasthenia gravis; severe arrhythmias or heart disease; Subjects after neurosurgery operation; participants who did not require continuous sedation during mechanical ventilation for endotracheal intubation; Abnormal values of the laboratory examination Subjects who required vasopressor medication to maintain normotensive blood pressure during the screening period (excluding subjects who used vasopressor medication only during surgery); Allergic to relevant drugs ingredient or component; Pregnant or nursing women; Subjects who has participated in clinical trials of other interventions recently; Other conditions deemed unsuitable to be included.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Qin Liu, M.M
Phone
+0518-82342973
Email
qin.liu@hengrui.com
Facility Information:
Facility Name
The Affiliated Hospital of Guizhou Medical University
City
Guiyang
State/Province
Guizhou
ZIP/Postal Code
550001
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Feng Shen

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

A Study of Remimazolam Tosilate for Prolonged Sedation in the ICU

We'll reach out to this number within 24 hrs